RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+88.23%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.13B
AUM Growth
+$1.97B
(+62%)
Cap. Flow
+$1.15B
Cap. Flow
% of AUM
22.34%
Top 10 Holdings %
Top 10 Hldgs %
55.31%
Holding
66
New
18
Increased
9
Reduced
12
Closed
9
Top Buys
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$419M |
| 2 |
Novavax
NVAX
|
$397M |
| 3 |
Vaxcyte
PCVX
|
$174M |
| 4 |
MacroGenics
MGNX
|
$128M |
| 5 |
Legend Biotech
LEGN
|
$106M |
Top Sells
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$233M |
| 2 |
Exelixis
EXEL
|
$77.9M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
$43.2M |
| 4 |
Gilead Sciences
GILD
|
$41M |
| 5 |
Relmada Therapeutics
RLMD
|
$23.6M |
Sector Composition
| 1 | Healthcare | 93.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Geron
GERN
$880M
| $65.7M | 1.28% |
+30,126,299
| New | +$65.7M |
|
27
89bio
ETNB
$1.28B
| $63M | 1.23% |
3,161,214
| – | – |
|
|
AKUS
28
DELISTED
Akouos, Inc. Common Stock
AKUS
| $51.3M | 1% |
+2,281,249
| New | +$51.3M |
|
|
TRIL
29
DELISTED
Trillium Therapeutics Inc.
TRIL
| $49.9M | 0.97% |
6,162,694
-198,752
| -3% | -$1.61M |
|
|
ORTX
30
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $45.7M | 0.89% |
1,040,319
+3,853
| +0.4% | +$169K |
|
31
Ardelyx
ARDX
$1.58B
| $43.3M | 0.84% |
6,260,904
-155,780
| -2% | -$1.08M |
|
32
Crinetics Pharmaceuticals
CRNX
$3.23B
| $40.8M | 0.8% |
2,328,698
+367,489
| +19% | +$6.44M |
|
|
33
Relmada Therapeutics
RLMD
$45.5M
| $38.1M | 0.74% |
851,907
-528,081
| -38% | -$23.6M |
|
|
PRVL
34
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $37.2M | 0.72% |
2,494,691
-745,843
| -23% | -$11.1M |
|
35
Arcutis Biotherapeutics
ARQT
$1.94B
| $35.2M | 0.69% |
1,165,184
| – | – |
|
36
Stoke Therapeutics
STOK
$1.08B
| $26.7M | 0.52% |
1,119,963
| – | – |
|
37
scPharmaceuticals
SCPH
$300M
| $25.9M | 0.5% |
3,518,998
| – | – |
|
|
AVDL
38
Avadel Pharmaceuticals
AVDL
$1.46B
| $25.3M | 0.49% |
+3,126,131
| New | +$25.3M |
|
39
Enliven Therapeutics
ELVN
$1.19B
| $22.9M | 0.45% |
207,337
-156,250
| -43% | -$17.3M |
|
40
Ocular Therapeutix
OCUL
$2.21B
| $22.7M | 0.44% |
+2,727,272
| New | +$22.7M |
|
41
Larimar Therapeutics
LRMR
$331M
| $19.5M | 0.38% |
+1,515,151
| New | +$19.5M |
|
|
CNCE
42
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $18.5M | 0.36% |
1,858,474
| – | – |
|
43
Verastem
VSTM
$650M
| $15.7M | 0.31% |
760,771
-789,617
| -51% | -$16.3M |
|
44
Syndax Pharmaceuticals
SNDX
$1.39B
| $15.2M | 0.3% |
+1,023,067
| New | +$15.2M |
|
45
Celldex Therapeutics
CLDX
$1.51B
| $15M | 0.29% |
+1,150,000
| New | +$15M |
|
46
Sutro Biopharma
STRO
$86.5M
| $14.9M | 0.29% |
+1,919,644
| New | +$14.9M |
|
47
Solid Biosciences
SLDB
$433M
| $13.4M | 0.26% |
304,744
| – | – |
|
48
Repare Therapeutics
RPTX
$72.6M
| $12.7M | 0.25% |
+409,000
| New | +$12.7M |
|
49
Lyra Therapeutics
LYRA
$11.6M
| $9.25M | 0.18% |
+16,317
| New | +$9.25M |
|
50
Passage Bio
PASG
$22.3M
| $8.82M | 0.17% |
16,132
| – | – |
|